AsthmaPhase 3NCT00076076
The FLASH Study: A Study of Roflumilast Versus Placebo in Patients With Asthma (BY217/M2-023)
A Phase 3 study testing Roflumilast in people with Asthma, run by AstraZeneca at 41 sites in 3 countries.
Trial summary
The purpose of this study is to confirm the dose of roflumilast to be used for asthma management by comparing the effects of 250 mcg and 500 mcg oral roflumilast with placebo on pulmonary function and asthma symptoms. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Asthma
- What is being tested?
- Roflumilast
- How many people
- 822 participants
- Where
- 41 sitesin 3 countries
- Study dates
- Dec 2003to Jun 2005
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Main Inclusion Criteria:
- Diagnosis of persistent chronic bronchial asthma
- Baseline lung function within specified parameters
- No change in asthma treatment during the last 4 weeks prior to start of baseline period
- Stable clinical state
- Except for asthma, in good health
- Non-smokers or ex-smokers
Main Exclusion Criteria:
- Poorly controlled asthma
- Diagnosis of chronic pulmonary disease and/or other relevant lung diseases
- Patients using continuously (more than 3 days per week) > 8 puffs/day rescue medication
Trial locations and contacts
41 sites in 3 countries.
41 sites in 3 countries
United States39 sites
ALTANA Pharma
Cities in Alabama, Alabama
ALTANA Pharma
Cities in Arizona, Arizona
ALTANA Pharma
Cities in Arkansas, Arkansas
ALTANA Pharma
Cities in California, California
ALTANA Pharma
Cities in Colorado, Colorado
ALTANA Pharma
Cities in Connecticut, Connecticut
ALTANA Pharma
Cities in Delaware, Delaware
ALTANA Pharma
Cities in Florida, Florida
ALTANA Pharma
Cities in Georgia, Georgia
ALTANA Pharma
Cities in Illinois, Illinois
ALTANA Pharma
Cities in Indiana, Indiana
ALTANA Pharma
Cities in Kansas, Kansas
ALTANA Pharma
Cities in Kentucky, Kentucky
ALTANA Pharma
Cities in Louisiana, Louisiana
ALTANA Pharma
Cities in Maine, Maine
ALTANA Pharma
Cities in Maryland, Maryland
ALTANA Pharma
Cities in Massachusetts, Massachusetts
ALTANA Pharma
Cities in Michigan, Michigan
ALTANA Pharma
Cities in Minnesota, Minnesota
ALTANA Pharma
Cities in Missouri, Missouri
ALTANA Pharma
Cities in Montana, Montana
ALTANA Pharma
Cities in Nebraska, Nebraska
ALTANA Pharma
Cities in Nevada, Nevada
ALTANA Pharma
Cities in New Jersey, New Jersey
ALTANA Pharma
Cities in New York, New York
ALTANA Pharma
Cities in North Carolina, North Carolina
ALTANA Pharma
Cities in Ohio, Ohio
ALTANA Pharma
Cities in Oklahoma, Oklahoma
ALTANA Pharma
Cities in Oregon, Oregon
ALTANA Pharma
Cities in Pennsylvania, Pennsylvania
ALTANA Pharma
Cities in Rhode Island, Rhode Island
ALTANA Pharma
Cities in South Carolina, South Carolina
ALTANA Pharma
Cities in Tennessee, Tennessee
ALTANA Pharma
Cities in Texas, Texas
ALTANA Pharma
Cities in Utah, Utah
ALTANA Pharma
Cities in Vermont, Vermont
ALTANA Pharma
Cities in Virginia, Virginia
ALTANA Pharma
Cities in Washington, Washington
ALTANA Pharma
Cities in West Virginia, West Virginia
About this study
Official title: The FLASH Study: A Randomized, Controlled Study of Roflumilast 250 mcg and 500 mcg Versus Placebo in Patients With Asthma
The purpose of this study is to confirm the dose of roflumilast to be used for asthma management by comparing the effects of 250 mcg and 500 mcg oral roflumilast with placebo on pulmonary function and asthma symptoms.
- Conditions
- Asthma
- Being tested
- Roflumilast
- Keywords
- Roflumilast, Asthma
- Medical subject headings
- Asthma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RoflumilastDrug
What is being measured
The primary outcome is the main question the study is designed to answer.
change in lung function.
Secondary outcomes (4)
change in morning PEF
asthma symptom score
rescue medication
time to withdrawal due to worsening asthma.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Jan 2004 (estimated)
- Study startDec 2003
- Study completionJun 2005
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for AsthmaStudies of the same condition, open and under way.
- More trials run by AstraZenecaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Enrolment
- 822 participants
Sponsor and investigators
- Lead sponsor
- AstraZeneca
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- AstraZeneca AstraZeneca, Study director, AstraZeneca
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00076076
- Sponsor's protocol ID
- BY217/M2-023
- Status last verified
- Sep 2016
- First submitted
- 13 Jan 2004
- Last updated
- 2 Dec 2016
- Results posted
- No
Publications
Chervinsky P, Meltzer EO, Busse W, Ohta K, Bardin P, Bredenbroker D, Bateman ED. Roflumilast for asthma: Safety findings from a pooled analysis of ten clinical studies. Pulm Pharmacol Ther. 2015 Dec;35 Suppl:S28-34. doi: 10.1016/j.pupt.2015.11.003. Epub 2015 Nov 22.
PubMed 26612545Meltzer EO, Chervinsky P, Busse W, Ohta K, Bardin P, Bredenbroker D, Bateman ED. Roflumilast for asthma: Efficacy findings in placebo-controlled studies. Pulm Pharmacol Ther. 2015 Dec;35 Suppl:S20-7. doi: 10.1016/j.pupt.2015.10.006. Epub 2015 Oct 21.
PubMed 26498386
Study at a glance
From the registry record, last updated by the sponsor on 2 Dec 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The FLASH Study: A Randomized, Controlled Study of Roflumilast 250 mcg and 500 mcg Versus Placebo in Patients With Asthma
- ClinicalTrials.gov ID
- NCT00076076
- Acronym / sponsor ID
- BY217/M2-023
- Conditions
- Asthma
- Keywords
- Roflumilast, Asthma
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 822 participants
- Lead sponsor
- AstraZenecaIndustry (pharma, biotech, devices)
- Study start
- Dec 2003
- Study completion
- Jun 2005 (actual)
- First posted
- 15 Jan 2004 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to confirm the dose of roflumilast to be used for asthma management by comparing the effects of 250 mcg and 500 mcg oral roflumilast with placebo on pulmonary function and asthma symptoms.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Roflumilast | Drug | – |
Primary outcome
change in lung function.
4 secondary outcomes
change in morning PEF
asthma symptom score
rescue medication
time to withdrawal due to worsening asthma.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Dec 2016.
- Derived from this study: PubMed 26612545Chervinsky P, Meltzer EO, Busse W, Ohta K, Bardin P, Bredenbroker D, Bateman ED. Roflumilast for asthma: Safety findings from a pooled analysis of ten clinical studies. Pulm Pharmacol Ther. 2015 Dec;35 Suppl:S28-34. doi: 10.1016/j.pupt.2015.11.003. Epub 2015 Nov 22.
- Derived from this study: PubMed 26498386Meltzer EO, Chervinsky P, Busse W, Ohta K, Bardin P, Bredenbroker D, Bateman ED. Roflumilast for asthma: Efficacy findings in placebo-controlled studies. Pulm Pharmacol Ther. 2015 Dec;35 Suppl:S20-7. doi: 10.1016/j.pupt.2015.10.006. Epub 2015 Oct 21.
- BY217-M2-023-RDS-2007-01-23.pdfLink provided by the sponsor.
Related trials for Asthma
RecruitingPhase 1
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
Asthma
RecruitingPhase 1
A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive
Asthma, Mild Asthma
RecruitingPhase 3
A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma
Asthma Control
Active, not recruitingPhase 2/3
Local Antibiotic Delivery for Community Acquired Pneumonia
Community Acquired Pneumonia (CAP)
RecruitingPhase 2
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
Asthma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
AstraZeneca AstraZeneca study director
AstraZeneca
41 sites in 3 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Roflumilast in people with Asthma, run by AstraZeneca at 41 sites in 3 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Dec 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 41 sites in United States, Russia, Ukraine. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
change in lung function.. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00076076, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Dec 2016.